Abstract
Cutaneous melanoma (CM) is a malignancy with increasing occurrence. Its microRNA repertoire has been defined in a number studies, leading to candidates for biological and clinical relevance: miR-200a/b/c, miR-203, miR-205, miR-204, miR-211, miR-23b and miR-26a/b. Our work was aimed to validate the role of these candidate miRNAs in melanoma, using additional patients cohorts and in vitro cultures. miR-26a, miR-204 and miR-211 were more expressed in normal melanocytes, while miR-23b, miR-200b/c, miR-203 and miR-205 in epidermis and keratinocytes. None of the keratinocyte-related miRNAs was associated with any known mutation or with clinical covariates in melanoma. On the other hand, the loss of miR-204 was enriched in melanomas with NRAS sole mutation (Fisher exact test, P = 0.001, Log Odds = 1.67), and less frequent than expected in those harbouring CDKN2A mutations (Fisher exact test, P = 0.001, Log Odds - 1.09). Additionally, miR-204 was associated with better prognosis in two independent melanoma cohorts and its exogenous expression led to growth impairment in melanoma cell lines. Thus, miR-204 represents a relevant mechanism in melanoma, with potential prognostic value and its loss seems to act in the CDKN2A pathway, in cooperation with NRAS.
| Original language | English |
|---|---|
| Article number | 71 |
| Journal | Molecular Cancer |
| Volume | 17 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Mar 9 2018 |
Fingerprint
Keywords
- BRAF
- Breslow
- CDKN2A
- Keratinocyte
- Melanocyte
- Melanoma
- MicroRNA
- Non coding rna
- NRAS
- Somatic alterations
ASJC Scopus subject areas
- Molecular Medicine
- Oncology
- Cancer Research
Cite this
Loss of miR-204 expression is a key event in melanoma. / Galasso, Marco; Morrison, Carl; Minotti, Linda; Corrà, Fabio; Zerbinati, Carlotta; Agnoletto, Chiara; Baldassari, Federica; Fassan, Matteo; Bartolazzi, Armando; Vecchione, Andrea; Nuovo, Gerard J.; Di Leva, Gianpiero; D'Atri, Stefania; Alvino, Ester; Previati, Maurizio; Nickoloff, Brian J.; Croce, Carlo M.; Volinia, Stefano.
In: Molecular Cancer, Vol. 17, No. 1, 71, 09.03.2018.Research output: Contribution to journal › Letter
}
TY - JOUR
T1 - Loss of miR-204 expression is a key event in melanoma
AU - Galasso, Marco
AU - Morrison, Carl
AU - Minotti, Linda
AU - Corrà, Fabio
AU - Zerbinati, Carlotta
AU - Agnoletto, Chiara
AU - Baldassari, Federica
AU - Fassan, Matteo
AU - Bartolazzi, Armando
AU - Vecchione, Andrea
AU - Nuovo, Gerard J.
AU - Di Leva, Gianpiero
AU - D'Atri, Stefania
AU - Alvino, Ester
AU - Previati, Maurizio
AU - Nickoloff, Brian J.
AU - Croce, Carlo M.
AU - Volinia, Stefano
PY - 2018/3/9
Y1 - 2018/3/9
N2 - Cutaneous melanoma (CM) is a malignancy with increasing occurrence. Its microRNA repertoire has been defined in a number studies, leading to candidates for biological and clinical relevance: miR-200a/b/c, miR-203, miR-205, miR-204, miR-211, miR-23b and miR-26a/b. Our work was aimed to validate the role of these candidate miRNAs in melanoma, using additional patients cohorts and in vitro cultures. miR-26a, miR-204 and miR-211 were more expressed in normal melanocytes, while miR-23b, miR-200b/c, miR-203 and miR-205 in epidermis and keratinocytes. None of the keratinocyte-related miRNAs was associated with any known mutation or with clinical covariates in melanoma. On the other hand, the loss of miR-204 was enriched in melanomas with NRAS sole mutation (Fisher exact test, P = 0.001, Log Odds = 1.67), and less frequent than expected in those harbouring CDKN2A mutations (Fisher exact test, P = 0.001, Log Odds - 1.09). Additionally, miR-204 was associated with better prognosis in two independent melanoma cohorts and its exogenous expression led to growth impairment in melanoma cell lines. Thus, miR-204 represents a relevant mechanism in melanoma, with potential prognostic value and its loss seems to act in the CDKN2A pathway, in cooperation with NRAS.
AB - Cutaneous melanoma (CM) is a malignancy with increasing occurrence. Its microRNA repertoire has been defined in a number studies, leading to candidates for biological and clinical relevance: miR-200a/b/c, miR-203, miR-205, miR-204, miR-211, miR-23b and miR-26a/b. Our work was aimed to validate the role of these candidate miRNAs in melanoma, using additional patients cohorts and in vitro cultures. miR-26a, miR-204 and miR-211 were more expressed in normal melanocytes, while miR-23b, miR-200b/c, miR-203 and miR-205 in epidermis and keratinocytes. None of the keratinocyte-related miRNAs was associated with any known mutation or with clinical covariates in melanoma. On the other hand, the loss of miR-204 was enriched in melanomas with NRAS sole mutation (Fisher exact test, P = 0.001, Log Odds = 1.67), and less frequent than expected in those harbouring CDKN2A mutations (Fisher exact test, P = 0.001, Log Odds - 1.09). Additionally, miR-204 was associated with better prognosis in two independent melanoma cohorts and its exogenous expression led to growth impairment in melanoma cell lines. Thus, miR-204 represents a relevant mechanism in melanoma, with potential prognostic value and its loss seems to act in the CDKN2A pathway, in cooperation with NRAS.
KW - BRAF
KW - Breslow
KW - CDKN2A
KW - Keratinocyte
KW - Melanocyte
KW - Melanoma
KW - MicroRNA
KW - Non coding rna
KW - NRAS
KW - Somatic alterations
UR - http://www.scopus.com/inward/record.url?scp=85043479974&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043479974&partnerID=8YFLogxK
U2 - 10.1186/s12943-018-0819-8
DO - 10.1186/s12943-018-0819-8
M3 - Letter
C2 - 29523154
AN - SCOPUS:85043479974
VL - 17
JO - Molecular Cancer
JF - Molecular Cancer
SN - 1476-4598
IS - 1
M1 - 71
ER -